Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway.

Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR 3rd, Bordone L, Guarente L, Krainc D.

Nat Med. 2011 Dec 18;18(1):159-65. doi: 10.1038/nm.2559.

2.

Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease.

Bithell A, Johnson R, Buckley NJ.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1270-5. doi: 10.1042/BST0371270. Review.

PMID:
19909260
3.

Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

Li SH, Li XJ.

Trends Genet. 2004 Mar;20(3):146-54. Review.

PMID:
15036808
5.

Huntington's disease.

Davies S, Ramsden DB.

Mol Pathol. 2001 Dec;54(6):409-13. Review.

6.

Huntington's disease: underlying molecular mechanisms and emerging concepts.

Labbadia J, Morimoto RI.

Trends Biochem Sci. 2013 Aug;38(8):378-85. doi: 10.1016/j.tibs.2013.05.003. Review.

7.

Targeting cardiovascular disease with novel SIRT1 pathways.

Chong ZZ, Wang S, Shang YC, Maiese K.

Future Cardiol. 2012 Jan;8(1):89-100. doi: 10.2217/fca.11.76. Review.

8.

Sirtuin 1 deacetylase: a key regulator of hepatic lipid metabolism.

Kemper JK, Choi SE, Kim DH.

Vitam Horm. 2013;91:385-404. doi: 10.1016/B978-0-12-407766-9.00016-X. Review.

9.
10.

The ways and means that fine tune Sirt1 activity.

Revollo JR, Li X.

Trends Biochem Sci. 2013 Mar;38(3):160-7. doi: 10.1016/j.tibs.2012.12.004. Review.

11.

Identification of compounds which inhibit cytotoxicity associated with mutant Huntingtin protein expression.

Titus S, Elia N, Southall N, Zheng W, Marugan JJ, MacDonald M.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Mar 30 [updated 2011 Mar 11].

Supplemental Content

Support Center